With no direct federal funding for Zika research and mosquitoes already infecting Floridians with the virus, the University of Pittsburgh Graduate School of Public Health in collaboration with a Brazilian research foundation is funding research on its own.
During a public event Thursday, Pitt’s Cura Zika (Cure Zika) program announced six research grant winners, including four based at Pitt, with $400,000 available through a $200,000 contribution from the university that was matched by an anonymous donor.
Those studies, most already underway, focus on how the virus infects the mother’s placenta leading to infection of brain cells of the fetus, with others working to understand the infection process as a means of developing vaccines to stop the explosive pandemic in South American, Central America and Caribbean nations that has reached mainland United States.
“Given the fact there is no new funding through the government for Zika research, we need to do it ourselves, and so we are announcing awards for research to get things started,” said Donald S. Burke, dean of Pitt Public Health and the Cura Zika program director. “It is unconscionable that there isn’t any new government funding available for Zika research in the face of this epidemic that destroys the lives of infants and families.”
Through Cura Zika, Pitt is collaborating with FIOCRUZ — the Brazilian Ministry of Health’s Fundacao Oswaldo Cruz Foundation, described as the most prominent science and technology health institution in Latin America.
Zika is a mosquito-borne viral infection that can be sexually transmitted, with the potential to produce microcephaly in infants born to mothers infected with the virus. That birth defect involves a smaller head and smaller brain, which might not have developed properly. The Zika virus also increases the risk of Guillain-Barre Syndrome and other neurological disorders in people who’ve contracted the infection, Cura Zika said in its announcement.
Pitt-based projects include the following:
• Jennifer Adibi, an assistant professor at Pitt Public Health, said her study will focus on the viral impact on the placenta during the first trimester of pregnancy, including how and when the infection actually occurs, with hope of determining the best timeline to prevent infections and understand when the fetus is most prone to developing microcephaly, among other details.
• How dendritic cells — the quarterbacks of the immune system — respond to the Zika virus infection is the focus of research by Robbie Mailliard, also an assistant professor at Pitt Public Health. It’s still unclear, he said, whether a vaccine could be used to prompt the dendritic cells to activate T-cells to foster a better attack against the virus. One problem is that previous exposures to viral infections including Dengue and even West Nile might confuse rather than enhance an effective immune response.
That variation in the immune process adds to the difficulty in developing a vaccine but also could provide a vaccine target, he said.
• Isabelle Freire Tabosa Viana, a postdoctoral associate at Pitt Public Health, is using innovative technologies to develop a non-viral DNA vaccine against the Zika virus. The vaccine involves DNA coding for the virus proteins and for a protein called LAMP (lysosomal-associated membrane protein). That combination along with a molecular enhancement is intended to generate a strong immune response against the virus and protect against infection, she said.
• Vishwajit Nimgaonkar, a professor in Pitt’s department of psychiatry and human genetics, is modeling Zika infections with the use of human brain cells (neurons) to understand not only how infection occurs in the brain but how best to block the infectious process.
Two Brazilian studies also are receiving funding, with all six studies involving collaboration among all Cura Zika researchers.
“Each study will receive funding for one year, and we expect additional funding downstream,” Dr. Burke said. “These are pilot projects to develop data and lead to greater funding from other agencies and hopefully Zika funding through the government.”
David Templeton: dtempleton@post-gazette.com or 412-263-1578.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.